The Patent Finder

Chirogate International Inc.

28 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

1
Ending by 2030
Apr 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 25, 2027
    The maintenance fee for Processes and intermediates for the preparations of isomer free prostaglandins (US 9,115,109) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
  • 1 fee due Apr 29, 2027
    The maintenance fee for Process for the preparation of Lubiprostone and intermediates thereof (US 10,457,623) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 2 fees due Jul 30, 2027
  • 2 fees due Sep 3, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,546,114Processes for the preparation of optically active cyclopentenones and cyclopentenones prepared therefrom
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,350,090Processes for preparing cyclopentenones and cyclopentenones for the synthesis of benzindene prostaglandins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,658,837Intermediates for the synthesis of benzindene prostaglandins and preparations thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,524,939Intermediates for the synthesis of benzindene prostaglandins and preparations thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,464,028Processes and intermediates for the preparations of isomer free prostaglandins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,540,311Processes and intermediates for the preparations of isomer free prostaglandins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,828,356Processes and intermediates for the preparations of isomer free prostaglandis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,890,135Processes and intermediates for the preparations of isomer free prostaglandins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,994,543Processes and intermediates for the preparations of isomer free prostaglandins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,822,321Processes and intermediates for the preparations of isomer free prostaglandins
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 28 patents shown.
Pro members see all 28.
Pro members: see all 28 patents
Also on record, not counted in the 28: 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited